130 related articles for article (PubMed ID: 36483226)
1. Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexibledosing etanercept in patients with plaque psoriasis in Greece.
Rigopoulos D; Patsatsi A; Antoniou C; Sotiriadis D; Schulze AR; Boubouchairopoulou N; Skiadas I; Tsekouras V; Hernandez Daly AC
Dermatol Reports; 2022 Nov; 14(4):9265. PubMed ID: 36483226
[TBL] [Abstract][Full Text] [Related]
2. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
[TBL] [Abstract][Full Text] [Related]
3. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
4. Real-world clinical outcomes of treatment with brodalumab in patients with moderate-to-severe psoriasis: a retrospective, 24-month experience from four academic dermatology centers in Greece.
Papadavid E; Zafeiriou E; Georgiou S; Roussaki-Schulze AV; Spiliopoulos T; Vryzaki E; Oikonomou C; Drongoula O; Boziou M; Goudouras G; Sfaelos K; Apalla Z; Lazaridou E
J Dermatolog Treat; 2022 Nov; 33(7):3053-3059. PubMed ID: 36000186
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
Ioannides D; Antonakopoulos N; Georgiou S; Chasapi V; Katsantonis I; Drosos A; Rigopoulos D; Antoniou C; Anastasiadis G; Bassukas I; Ioannidou D; Protopapa A; Neofotistou O; Krasagakis K; Aronis P; Papageorgiou M; Lazaridou E; Patsatsi A; Lefaki I; Roussaki-Schulze AV; Satra F; Anagnostopoulos Z; Papakonstantis M
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1838-1848. PubMed ID: 34036627
[TBL] [Abstract][Full Text] [Related]
6. An observational study to evaluate the long-term outcomes of treatment with etanercept in patients with plaque-type psoriasis.
Luger T; Schopf RE; Schwanke A; Langhammer S; Meng T; Löschmann PA
J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1730-1741. PubMed ID: 27297981
[TBL] [Abstract][Full Text] [Related]
7. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
8. Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study.
Pinter A; Soliman AM; Pivneva I; Ghanbariamin R; Yang M; Truong B; Puig L; Lebwohl M
Dermatol Ther (Heidelb); 2024 May; 14(5):1259-1271. PubMed ID: 38727996
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
10. Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuation.
Arcese A; Aste N; Bettacchi A; Camplone G; Cantoresi F; Caproni M; D'Amico D; Fabbri P; Filosa G; Galluccio A; Hansel K; Lisi P; Micali G; Musumeci ML; Nicolini M; Parodi A; Patania M; Pezza M; Potenza C; Richetta A; Simonacci M; Trevisan P; Valenti G; Calvieri S
Clin Drug Investig; 2010; 30(8):507-16. PubMed ID: 20586516
[TBL] [Abstract][Full Text] [Related]
11. Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.
Bagel J; Samad AS; Stolshek BS; Aras GA; Chung JB; Kricorian G; Kircik LH
J Drugs Dermatol; 2018 Oct; 17(10):1078-1082. PubMed ID: 30365588
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab Demonstrated High Effectiveness in Vietnamese Patients with Moderate-To-Severe Plaque Psoriasis in a Real-World Clinical Setting: 16 Week Results from an Observational Study.
Nguyen HT; Pham NTU; Tran TNA; Nguyen NTT; Vu TTP
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1613-1621. PubMed ID: 34275123
[TBL] [Abstract][Full Text] [Related]
13. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
Vender R
J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
Petridis A; Panagakis P; Moustou E; Vergou T; Kallidis P; Mandekou-Lefaki I; Chaidemenos G; Sotiriadis D; Alexopoulou G; Haratsis Y; Antoniou C
J Eur Acad Dermatol Venereol; 2018 May; 32(5):768-775. PubMed ID: 29356149
[TBL] [Abstract][Full Text] [Related]
15. Clinical and economic impact of etanercept in real-life: a prospective, non-interventional study of etanercept in the treatment of patients with moderate to severe plaque psoriasis in private dermatologist settings (ESTHER).
Larsen CG; Andersen PH; Lorentzen H; Zachariae C; Huldt-Nystrøm T; Dotterud LK; Lindkvist RM; Qvitzau S
Eur J Dermatol; 2013; 23(6):774-81. PubMed ID: 24334009
[TBL] [Abstract][Full Text] [Related]
16. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
17. A real-world, non-interventional, prospective study of the effectiveness and safety of apremilast in bio-naïve adults with moderate plaque psoriasis treated in the routine care in Greece - the 'APRAISAL' study.
Ioannides D; Antonakopoulos N; Chasapi V; Oikonomou C; Tampouratzi E; Lazaridou E; Rigopoulos D; Neofotistou O; Drosos A; Anastasiadis G; Rovithi E; Kalinou C; Papadavid E; Aronis P; Papageorgiou M; Protopapa A; Bassukas I; Lefaki I; Zafiriou E; Krasagakis K; Pokas E; Anagnostopoulos Z; Kekki A; Papakonstantis M
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2055-2063. PubMed ID: 35451115
[TBL] [Abstract][Full Text] [Related]
18. Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program.
Gulliver W; Gooderham MJ; Zhu B; Jossart C; Montmayeur S; Burge R; Reed C
Dermatol Ther (Heidelb); 2023 Jan; 13(1):235-244. PubMed ID: 36436161
[TBL] [Abstract][Full Text] [Related]
19. Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO.
Reich K; Korge B; Magnolo N; Manasterski M; Schwichtenberg U; Staubach-Renz P; Kaiser S; Roemmler-Zehrer J; Gómez NN; Lorenz-Baath K
Dermatol Ther (Heidelb); 2022 Jan; 12(1):203-221. PubMed ID: 34913153
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
